A Novel Diagnostic Model for Primary Adrenal Lymphoma

ObjectivePrimary adrenal lymphoma (PAL) is easily misdiagnosed as other adrenal masses, such as adrenocortical carcinoma and pheochromocytoma, but patients with PAL benefit little from surgery. The diagnostic method for PAL thus far is limited to adrenal biopsy. In our study, we aimed to develop a q...

Full description

Bibliographic Details
Main Authors: Kai Yu, Qingping Xue, Fangli Zhou, Haoming Tian, Qiao Xiang, Tao Chen, Yan Ren
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.636658/full
id doaj-6716f7fe1412436b8e60a3406db2d95d
record_format Article
spelling doaj-6716f7fe1412436b8e60a3406db2d95d2021-04-02T04:18:17ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-04-011210.3389/fendo.2021.636658636658A Novel Diagnostic Model for Primary Adrenal LymphomaKai Yu0Qingping Xue1Qingping Xue2Fangli Zhou3Haoming Tian4Qiao Xiang5Tao Chen6Yan Ren7Adrenal Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Public Health, Chengdu Medical College, Chengdu, ChinaWest China School of Public Health, West China Fourth Hospital, Sichuan University, Chengdu, ChinaAdrenal Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, ChinaAdrenal Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, ChinaAdrenal Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, ChinaAdrenal Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, ChinaAdrenal Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, ChinaObjectivePrimary adrenal lymphoma (PAL) is easily misdiagnosed as other adrenal masses, such as adrenocortical carcinoma and pheochromocytoma, but patients with PAL benefit little from surgery. The diagnostic method for PAL thus far is limited to adrenal biopsy. In our study, we aimed to develop a quick and efficient diagnostic method for PAL.Methods and ResultsAt the same institution, 505 patients (between 2009 and 2019) and 171 patients (between 2019 and 2020) were separately included in the primary and validation studies. Univariate and multivariate analyses were conducted to evaluate clinical manifestations, laboratory findings, and radiological characteristics. Four determinants (age, bilateral masses, high-density lipoprotein cholesterol, and lactate dehydrogenase) were selected and further incorporated into a regression model to screen PAL. Accordingly, the nomogram was developed for clinical practice. In the primary study, the nomogram showed good discrimination, with an area under the receiver operating characteristic (ROC) curve (AUC) of 95.4% (95% CI, 90.6%–100.0%). Further validation study verified the efficacy of the nomogram, with an AUC of 99.0% (95% CI, 96.9%–100.00%) and 100.0% in all patients and patients with bilateral masses, respectively, and a sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV) of 66.67%/99.40%/66.67%/99.40%, 66.67%/100%/100%/92.86%, 50%/99.20%/50%/99.20%, and 100%/100%/100%/100%, in all patients, patients with bilateral adrenal masses, patients with nonfunctional adrenal masses, and patients with positive catecholamine results, respectively. The validation study also revealed a diagnostic specificity of 99.35% and 100% for patients with a unilateral adrenal mass and functional PCC, respectively.ConclusionsThe presented nomogram is the first user-friendly diagnostic model for PAL that simplifies the complex diagnostic process into personalized numeric estimates. We deem that patients who score below 50 are less likely to have PAL. We suggest that clinicians should arrange adrenal biopsy and surgery for patients with nonfunctional tumors and overt catecholamine-secreting tumors, respectively, who receive a score of 50 points or higher to confirm the diagnosis as soon as possible.https://www.frontiersin.org/articles/10.3389/fendo.2021.636658/fullprimary adrenal lymphomanonfunctional adrenal masspheochromocytomadiagnosisnomogram
collection DOAJ
language English
format Article
sources DOAJ
author Kai Yu
Qingping Xue
Qingping Xue
Fangli Zhou
Haoming Tian
Qiao Xiang
Tao Chen
Yan Ren
spellingShingle Kai Yu
Qingping Xue
Qingping Xue
Fangli Zhou
Haoming Tian
Qiao Xiang
Tao Chen
Yan Ren
A Novel Diagnostic Model for Primary Adrenal Lymphoma
Frontiers in Endocrinology
primary adrenal lymphoma
nonfunctional adrenal mass
pheochromocytoma
diagnosis
nomogram
author_facet Kai Yu
Qingping Xue
Qingping Xue
Fangli Zhou
Haoming Tian
Qiao Xiang
Tao Chen
Yan Ren
author_sort Kai Yu
title A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_short A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_full A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_fullStr A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_full_unstemmed A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_sort novel diagnostic model for primary adrenal lymphoma
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2021-04-01
description ObjectivePrimary adrenal lymphoma (PAL) is easily misdiagnosed as other adrenal masses, such as adrenocortical carcinoma and pheochromocytoma, but patients with PAL benefit little from surgery. The diagnostic method for PAL thus far is limited to adrenal biopsy. In our study, we aimed to develop a quick and efficient diagnostic method for PAL.Methods and ResultsAt the same institution, 505 patients (between 2009 and 2019) and 171 patients (between 2019 and 2020) were separately included in the primary and validation studies. Univariate and multivariate analyses were conducted to evaluate clinical manifestations, laboratory findings, and radiological characteristics. Four determinants (age, bilateral masses, high-density lipoprotein cholesterol, and lactate dehydrogenase) were selected and further incorporated into a regression model to screen PAL. Accordingly, the nomogram was developed for clinical practice. In the primary study, the nomogram showed good discrimination, with an area under the receiver operating characteristic (ROC) curve (AUC) of 95.4% (95% CI, 90.6%–100.0%). Further validation study verified the efficacy of the nomogram, with an AUC of 99.0% (95% CI, 96.9%–100.00%) and 100.0% in all patients and patients with bilateral masses, respectively, and a sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV) of 66.67%/99.40%/66.67%/99.40%, 66.67%/100%/100%/92.86%, 50%/99.20%/50%/99.20%, and 100%/100%/100%/100%, in all patients, patients with bilateral adrenal masses, patients with nonfunctional adrenal masses, and patients with positive catecholamine results, respectively. The validation study also revealed a diagnostic specificity of 99.35% and 100% for patients with a unilateral adrenal mass and functional PCC, respectively.ConclusionsThe presented nomogram is the first user-friendly diagnostic model for PAL that simplifies the complex diagnostic process into personalized numeric estimates. We deem that patients who score below 50 are less likely to have PAL. We suggest that clinicians should arrange adrenal biopsy and surgery for patients with nonfunctional tumors and overt catecholamine-secreting tumors, respectively, who receive a score of 50 points or higher to confirm the diagnosis as soon as possible.
topic primary adrenal lymphoma
nonfunctional adrenal mass
pheochromocytoma
diagnosis
nomogram
url https://www.frontiersin.org/articles/10.3389/fendo.2021.636658/full
work_keys_str_mv AT kaiyu anoveldiagnosticmodelforprimaryadrenallymphoma
AT qingpingxue anoveldiagnosticmodelforprimaryadrenallymphoma
AT qingpingxue anoveldiagnosticmodelforprimaryadrenallymphoma
AT fanglizhou anoveldiagnosticmodelforprimaryadrenallymphoma
AT haomingtian anoveldiagnosticmodelforprimaryadrenallymphoma
AT qiaoxiang anoveldiagnosticmodelforprimaryadrenallymphoma
AT taochen anoveldiagnosticmodelforprimaryadrenallymphoma
AT yanren anoveldiagnosticmodelforprimaryadrenallymphoma
AT kaiyu noveldiagnosticmodelforprimaryadrenallymphoma
AT qingpingxue noveldiagnosticmodelforprimaryadrenallymphoma
AT qingpingxue noveldiagnosticmodelforprimaryadrenallymphoma
AT fanglizhou noveldiagnosticmodelforprimaryadrenallymphoma
AT haomingtian noveldiagnosticmodelforprimaryadrenallymphoma
AT qiaoxiang noveldiagnosticmodelforprimaryadrenallymphoma
AT taochen noveldiagnosticmodelforprimaryadrenallymphoma
AT yanren noveldiagnosticmodelforprimaryadrenallymphoma
_version_ 1724173367307665408